A_DT new_JJ model_NN for_IN ductal_JJ carcinoma_NN in_IN situ_NN suggests_VBZ strategies_NNS for_IN treatment_NN Abstract_NP |_SYM Human_JJ ductal_JJ carcinoma_NN in_IN situ_NN (_( DCIS_NP )_) of_IN the_DT breast_NN is_VBZ now_RB diagnosed_VBN quite_RB frequently_RB ,_, due_JJ largely_RB to_TO the_DT introduction_NN of_IN mammographic_JJ screening_NN ._SENT It_PP has_VBZ been_VBN shown_VBN in_IN a_DT cell_NN culture_NN system_NN that_IN activation_NN of_IN c-erbB-2_NP ,_, but_CC not_RB the_DT epidermal_JJ growth_NN factor_NN receptor_NN ,_, results_NNS in_IN a_DT DCIS-like_JJ phenotype_NN ._SENT Since_IN overexpression_NN of_IN c-erbB-2_NP occurs_VBZ in_IN 60_CD %_NN of_IN DCIS_NP ,_, this_DT suggests_VBZ that_IN it_PP could_MD be_VB a_DT target_NN for_IN treatment_NN in_IN this_DT disease_NN ._SENT ductal_JJ carcinoma_NN in_IN situ_NN ,_, growth_NN factor_NN receptor_NN ,_, tyrosine_NN kinase_NN inhibitor_NN ,_, Breast_NP pathologists_NNS have_VBP for_IN many_JJ years_NNS been_VBN seeking_VBG to_TO demonstrate_VB a_DT sequence_NN of_IN morphologically_RB distinguishable_JJ cellular_JJ changes_NNS that_WDT define_VBP a_DT linear_JJ sequence_NN of_IN transformation_NN of_IN normal_JJ breast_NN ductal_JJ epithelium_NN to_TO the_DT fully_RB malignant_JJ state_NN ._SENT It_PP is_VBZ still_RB not_RB entirely_RB clear_JJ that_IN this_DT has_VBZ been_VBN achieved_VBN ,_, but_CC a_DT general_JJ model_NN consists_VBZ of_IN premalignant_JJ changes_NNS (_( a_DT variety_NN of_IN hyperplasias_NNS )_) followed_VBN by_IN DCIS_NP with_IN subsequent_JJ invasive_JJ disease_NN ._SENT There_EX are_VBP alternative_JJ views_NNS that_IN these_DT changes_NNS are_VBP neither_RB linear_JJ nor_CC do_VB they_PP always_RB entail_VB each_DT intermediate_JJ phenotype_NN ._SENT Clinically_RB ,_, however_RB ,_, there_EX are_VBP clear_JJ distinctions_NNS between_IN these_DT stages_NNS in_IN terms_NNS of_IN the_DT risk_NN to_TO the_DT patient_NN ,_, which_WDT affects_VBZ the_DT choice_NN of_IN treatment_NN ._SENT It_PP has_VBZ been_VBN hoped_VBN that_IN the_DT description_NN of_IN the_DT underlying_VBG molecular_JJ changes_NNS accompanying_VBG these_DT morphologically_RB defined_VBN stages_NNS ,_, and_CC at_IN least_JJS a_DT partial_JJ understanding_NN of_IN their_PP$ significance_NN ,_, would_MD enable_VB pathologists_NNS to_TO confirm_VB or_CC refute_VB their_PP$ models_NNS and_CC to_TO allow_VB individual_JJ cases_NNS to_TO be_VB placed_VBN in_IN the_DT sequence_NN ._SENT This_DT has_VBZ to_TO some_DT extent_NN been_VBN achieved_VBN ;_: many_JJ molecular_JJ changes_NNS at_IN the_DT level_NN of_IN the_DT DNA_NP have_VBP been_VBN found_VBN in_IN DCIS_NP but_CC not_RB in_IN premalignant_JJ disease_NN ._SENT Somewhat_RB disappointingly_RB ,_, however_RB ,_, little_RB if_IN anything_NN is_VBZ known_VBN definitively_RB about_IN any_DT additional_JJ molecular_JJ changes_NNS that_WDT are_VBP presumed_VBN to_TO result_VB in_IN the_DT transition_NN from_IN DCIS_NP to_TO invasive_JJ disease_NN ._SENT Research_NP continues_VBZ into_IN this_DT problem_NN using_VBG methods_NNS that_WDT minimise_VBP preconceptions_NNS such_JJ as_IN genomic_JJ analysis_NN and_CC gene_NN expression_NN analysis_NN ._SENT The_DT molecular_JJ changes_NNS seen_VBN in_IN DCIS_NP include_VBP mutations_NNS in_IN the_DT p53_NN gene_NN ,_, and_CC gene_NN amplification_NN and_CC overexpression_NN at_IN the_DT protein_NN level_NN of_IN the_DT c-erbB-2_NP receptor_NN tyrosine_NN kinase_NN ._SENT There_EX is_VBZ a_DT higher_JJR prevalence_NN of_IN both_CC these_DT events_NNS in_IN more_JJR undifferentiated_JJ DCIS_NP (_( known_VBN as_IN comedo_NN cancer_NN in_IN previous_JJ terminologies_NNS )_) ,_, suggesting_VBG a_DT functional_JJ significance_NN ,_, but_CC this_DT had_VBD not_RB been_VBN definitively_RB established_VBN ._SENT like_IN phenotype_NN :_: The_DT hypothesis_NN that_IN growth_NN factor_NN receptor_NN activation_NN leads_VBZ to_TO a_DT DCIS-like_JJ phenotype_NN is_VBZ tested_VBN in_IN an_DT article_NN by_IN Muthuswamy_NP et_FW al._FW ._SENT Two_CD groups_NNS cooperated_VBN in_IN that_DT work_NN ,_, each_DT bringing_VBG a_DT different_JJ technological_JJ contribution_NN ._SENT Mina_NP Bissell_NP ,_, the_DT doyen_NN of_IN breast_NN cancer_NN cell_NN biologists_NNS ,_, developed_VBD three-dimensional_JJ cell_NN culture_NN models_NNS of_IN normal_JJ breast_NN epithelial_JJ cells_NNS over_IN several_JJ years_NNS ._SENT Joan_NP Brugge_NP explored_VBD the_DT mechanisms_NNS of_IN growth_NN factor_NN receptor_NN signalling_VBG and_CC developed_VBD a_DT system_NN in_IN which_WDT ectopically_RB expressed_VBD receptors_NNS can_MD be_VB selectively_RB activated_VBN at_IN will_NN by_IN the_DT addition_NN of_IN drugs_NNS ._SENT The_DT c-erbB-2_NP protein_NN ,_, which_WDT is_VBZ overexpressed_VBN in_IN DCIS_NP ,_, is_VBZ a_DT member_NN of_IN the_DT epidermal_JJ growth_NN factor_NN receptor_NN (_( EGFR_NP )_) family_NN ._SENT This_DT family_NN consists_VBZ of_IN the_DT EGFR_NP ,_, c-erbB-2_NP and_CC two_CD more_JJR receptors_NNS (_( c-erbB-3_NP and_CC c-erbB-4_NP )_) ._SENT Each_DT protein_NN has_VBZ an_DT extracellular_JJ domain_NN ,_, which_WDT in_IN some_DT cases_NNS recognises_VBZ an_DT activating_VBG ligand_NN ,_, a_DT transmembrane_NN domain_NN and_CC a_DT cytoplasmic_JJ domain_NN with_IN protein_NN tyrosine_NN kinase_NN enzyme_NN activity_NN ._SENT Ligand_NN binding_NN induces_VBZ receptor_NN dimerisation_NN ,_, activation_NN of_IN the_DT kinase_NN and_CC phosphorylation_NN of_IN tyrosine_NN residues_NNS in_IN the_DT cytoplasmic_JJ domain_NN ._SENT The_DT phosphorylated_JJ protein_NN then_RB recruits_VBZ and_CC activates_VBZ a_DT variety_NN of_IN intracellular_JJ second_JJ messenger_NN systems_NNS that_WDT induce_VBP changes_NNS to_TO the_DT cytoskeleton_NN and_CC that_WDT can_MD stimulate_VB the_DT rate_NN of_IN cell_NN division_NN ._SENT Brugge_NP and_CC colleagues_NNS have_VBP constructed_VBN altered_JJ receptors_NNS in_IN which_WDT the_DT extracellular_JJ domain_NN is_VBZ derived_VBN from_IN the_DT nerve_NN growth_NN factor_NN receptor_NN and_CC cytoplasmic_JJ domains_NNS from_IN either_CC the_DT EGFR_NP or_CC the_DT c-erbB-2_NP receptor_NN ._SENT In_IN addition_NN ,_, however_RB ,_, there_EX is_VBZ a_DT sequence_NN fused_VBD to_TO the_DT C-termini_NP of_IN the_DT constructs_NNS derived_VBN from_IN the_DT FK506-binding_NP protein_NN ._SENT The_DT membrane-permeable_JJ bivalent_JJ compound_NN AP1510_NP binds_VBZ to_TO this_DT region_NN and_CC induces_VBZ dimerisation_NN ,_, phosphorylation_NN and_CC intracellular_JJ signal_NN transduction_NN ,_, allowing_VBG selective_JJ ,_, acute_JJ or_CC chronic_JJ receptor_NN activation_NN ._SENT In_IN the_DT study_NN reported_VBD in_IN Nature_NP Cell_NP Biology_NP ,_, Muthuswamy_NP et_FW al._FW introduced_VBD the_DT chimeric_JJ EGFR_NP and_CC c-erbB-2_NP separately_RB into_IN MCF10A_NP cells_NNS (_( immortal_JJ but_CC untransformed_JJ human_JJ mammary_JJ epithelial_JJ cells_NNS )_) and_CC established_VBN stable_JJ lines_NNS expressing_VBG moderate_JJ levels_NNS of_IN either_DT receptor_NN ._SENT In_IN the_DT absence_NN of_IN AP1510_NP ,_, these_DT grew_VBD in_IN three-dimensional_JJ cultures_NNS ,_, indistinguishable_JJ from_IN the_DT untransfected_JJ cells_NNS ,_, as_IN structures_NNS highly_RB reminiscent_JJ of_IN mammary_JJ epithelial_JJ acini_NNS ._SENT Each_DT acinar_JJ structure_NN contained_VBD approximately_RB 20_CD --_: 40_CD cells_NNS with_IN basally_RB located_VBN nuclei_NNS and_CC a_DT lumen_NN ._SENT Staining_VBG for_IN cell_NN adhesion_NN molecules_NNS showed_VBD that_IN the_DT cells_NNS were_VBD polarised_VBN and_CC surrounded_VBN by_IN a_DT collagen_NN layer_NN similar_JJ to_TO a_DT basement_NN membrane_NN ._SENT The_DT chimeric_JJ EGFR_NP was_VBD able_JJ to_TO stimulate_VB growth_NN of_IN the_DT MCF10A_NP cells_NNS in_IN monolayer_NN culture_NN ,_, demonstrating_VBG that_IN it_PP was_VBD functional_JJ ,_, but_CC activation_NN by_IN the_DT addition_NN of_IN AP1510_NP had_VBD no_DT effect_NN on_IN cell_NN behaviour_NN or_CC morphology_NN when_WRB the_DT cells_NNS were_VBD grown_VBN in_IN three-dimensional_JJ cultures_NNS ._SENT Strikingly_RB ,_, however_RB ,_, activation_NN of_IN the_DT c-erbB-2_NP protein_NN caused_VBD marked_JJ changes_NNS in_IN the_DT polarised_VBN acinar_JJ structures_NNS ._SENT These_DT lost_VBD their_PP$ polarised_VBN organisation_NN and_CC grew_VBD into_IN structures_NNS described_VBN as_RB '_'' consisting_VBG of_IN multiple_JJ acinar-like_JJ units_NNS with_IN filled_VBN lumina_NN '_'' ;_: in_IN some_DT cases_NNS ,_, a_DT hundred_CD times_NNS the_DT size_NN of_IN untreated_JJ structures_NNS ._SENT Muthuswamy_NP et_FW al._FW conclude_VBP that_IN the_DT EGFR_NP and_CC c-erbB-2_NN '_'' have_VB different_JJ abilities_NNS to_TO affect_VB polarised_VBN and_CC growth_NN arrested_VBN acini_NNS '_'' and_CC that_IN '_POS acute_JJ activation_NN of_IN c-erbB-2_NP results_NNS in_IN the_DT generation_NN of_IN multi-acinar_JJ structures_NNS that_IN share_NN properties_NNS with_IN structures_NNS associated_VBN with_IN carcinoma_NN in_IN situ_NN '_POS ._SENT DCIS_NP is_VBZ often_RB treated_VBN surgically_RB by_IN mastectomy_NN rather_RB than_IN breast-conserving_VBG surgery_NN since_IN it_PP is_VBZ commonly_RB multifocal_JJ and_CC sometimes_RB extensive_JJ ._SENT Failure_NN to_TO completely_RB remove_VB the_DT disease_NN is_VBZ associated_VBN with_IN a_DT low_JJ but_CC significant_JJ probability_NN of_IN the_DT subsequent_JJ development_NN of_IN invasive_JJ cancer_NN ._SENT It_PP would_MD be_VB highly_RB desirable_JJ to_TO identify_VB effective_JJ ,_, low-toxicity_JJ adjuvant_JJ therapy_NN that_WDT might_MD justify_VB the_DT use_NN of_IN more_JJR limited_JJ surgery_NN ._SENT The_DT formal_JJ demonstration_NN by_IN Muthuswamy_NP et_FW al._FW that_IN overexpression_NN of_IN c-erbB-2_NN in_IN normal_JJ breast_NN ductal_JJ epithelial_JJ cells_NNS leads_VBZ to_TO a_DT DCIS-like_JJ phenotype_NN provides_VBZ strong_JJ support_NN for_IN studying_VBG such_JJ treatments_NNS in_IN more_JJR detail_NN in_IN model_NN systems_NNS ._SENT In_IN independent_JJ work_NN ,_, Bundred_NP and_CC coworkers_NNS have_VBP developed_VBN a_DT xenograft_NN system_NN in_IN which_WDT small_JJ pieces_NNS of_IN human_JJ DCIS_NP are_VBP implanted_VBN subcutaneously_RB in_IN nude_JJ mice_NNS where_WRB the_DT tissue_NN survives_VBZ and_CC grows_VBZ ._SENT Treatment_NN of_IN the_DT mice_NNS with_IN herceptin_NN (_( a_DT monoclonal_NN antibody_NN to_TO the_DT human_JJ c-erbB-2_NN protein_NN now_RB used_VBN for_IN the_DT treatment_NN of_IN some_DT invasive_JJ breast_NN cancers_NNS )_) did_VBD not_RB have_VB any_DT effect_NN ,_, but_CC treatment_NN with_IN iressa_NN (_( a_DT small-molecule_NN tyrosine_NN kinase_NN inhibitor_NN that_WDT acts_VBZ principally_RB on_IN the_DT EGFR_NP but_CC that_WDT will_MD also_RB ,_, at_IN higher_JJR concentrations_NNS ,_, inhibit_VB c-erbB-2_NP )_) did_VBD inhibit_VB cancer_NN cell_NN growth_NN ._SENT It_PP is_VBZ also_RB possible_JJ that_IN heterodimers_NNS between_IN EGFR_NP and_CC c-erbB-2_NP are_VBP important_JJ in_IN signalling_VBG in_IN this_DT context_NN ,_, and_CC that_IN these_DT will_MD also_RB be_VB inhibited_VBN to_TO a_DT degree_NN by_IN the_DT tyrosine_NN kinase_NN inhibitor_NN ._SENT The_DT presented_VBN results_NNS suggest_VBP that_IN antibodies_NNS may_MD not_RB be_VB the_DT first_JJ method_NN of_IN choice_NN for_IN treatment_NN of_IN DCIS_NP of_IN the_DT breast_NN because_IN they_PP are_VBP large_JJ molecules_NNS and_CC may_MD have_VB limited_VBN access_NN to_TO the_DT interior_NN of_IN the_DT cancer-filled_JJ duct_NN ._SENT Orally_RB available_JJ small-molecule_NN tyrosine_NN kinase_NN inhibitors_NNS are_VBP more_RBR promising_JJ ,_, and_CC several_JJ pharmaceutical_JJ companies_NNS have_VBP selective_JJ c-erbB-2/EGFR_NP inhibitors_NNS in_IN development_NN ._SENT Should_MD these_DT studies_NNS prove_VBP encouraging_VBG ,_, there_EX would_MD be_VB a_DT rationale_NN for_IN testing_VBG these_DT inhibitors_NNS in_IN cases_NNS of_IN ductal_JJ carcinoma_NN of_IN the_DT breast_NN in_IN clinical_JJ trials_NNS ._SENT DCIS_NN =_SYM ductal_JJ carcinoma_NN in_IN situ_NN ;_: EGFR_NP =_SYM epidermal_JJ growth_NN factor_NN receptor_NN ._SENT 